



*From Nature for Life*

## PRESS RELEASE

### **Biotest AG: Annual General Meeting approves dividend distribution**

- **Distribution of EUR 0.04 per preference share for each of the years 2023 and 2022**
- **Broad majority in the vote in line with the management's proposals**

*Dreieich, 07 May 2024.* At the Annual General Meeting on May 7, 2024, the shareholders of Biotest AG resolved to distribute a dividend of € 0.04 per preference share for the years 2023 and 2022. A total of 76.19% of the share capital was represented. The resolution on the appropriation of net profit was passed with 99.93% approval.

The shareholders approved the actions of the members of the Executive Board and Supervisory Board for the 2023 financial year by a large majority. All resolutions on the other items on the agenda submitted for resolution were also passed by a large majority in accordance with the management's proposals.

The Annual General Meeting speech by Mr. Peter Janssen, CEO of Biotest AG, is available at Annual General Meeting 2024 [Shareholders' Meeting 2024 \(biostest.com\)](https://www.biostest.com/shareholders-meeting-2024).

#### About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain ([www.grifols.com](http://www.grifols.com)).

#### About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain ([www.grifols.com](http://www.grifols.com)).

#### **IR contact**

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406

Mail: [ir@biostest.com](mailto:ir@biostest.com)

**PR contact**

Dirk Neumüller  
Phone: +49-6103-801-269  
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, [www.biotest.com](http://www.biotest.com)

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201  
Preference shares: securities' ID No. 522723; ISIN DE0005227235  
Listing: Frankfurt (Prime Standard)  
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

**Disclaimer**

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.